🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT04961450
Enrolling by invitation Observational

Explore Biomarkers of Motor Neuron Disease/Frontal Dementia Spectrum Disease in China

NCT04961450 · tracked via the Priya Life Science China tracker
Sponsor
Peking University Third Hospital
Phase
Observational
Started
2021-06-24
Last updated
2021-07-14

Condition(s) studied

Amyotrophic Lateral SclerosisFrontotemporal DementiaMotor Neuron Disease

Study summary

1. To investigate the biomarkers of MND/FTD spectrum disease
2. To explore the possible pathogenesis of MND/FTD

Eligibility

Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
No
Patients: Inclusion Criteria: 1. Patients aged 18-80 years who visit Peking University Third Hospital, Beijing, China from December 2020. Patients who diagnosis MND/FTD spectrum disease (including ALS, FAS, FLS, PLS, PBP, PMA, FTD, MND-FTD) by an experienced neurologist strictly according to a list of diagnosis criteria and clinical guidelines 2. Informed consent signed Exclusion Criteria * Patients who receive alternative diagnoses during the follow-up. * Patients who refuse to sign informed consent. Control group: Control group consists of individuals matched for gender and age with the patients who are mainly the caregivers of the patients, including but not limited to the patients' spouses and their long-term nurses. Exclusion criteria: 1. Suffering from neurological disease, including but not limited to motor neuron disease/frontotemporal dementia spectrum disease, dementia, Alzheimer's disease, Parkinson's disease, multiple sclerosis, neuromyelitis and so on. 2. Individuals who refuse to sign informed consent.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Dongsheng Fan Beijing Beijing Municipality

More Peking University Third Hospital trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04961450 on ClinicalTrials.gov ↗ ← All trials in China